| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 25041 |
| Drug | Acalabrutinib |
| Brand | Calquence® |
| Indication | Acalabrutinib (Calquence®) in combination with bendamustine and rituximab is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant (ASCT). |
| Assessment Process | |
| Rapid review commissioned | 30/06/2025 |
| Rapid review completed | 21/07/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of acalabrutinib in combination with bendamustine and rituximab compared with the current standard of care. |
| Full HTA commissioned by the HSE | 31/07/2025 |
| Pre-submission consultation with Applicant | 11/09/2025 |
| Full submission received from Applicant | 08/01/2026 |
| Preliminary review sent to Applicant | 15/05/2026 |
| NCPE assessment re-commenced | 12/06/2026 |
| Follow-up to preliminary review sent to Applicant | 09/07/2026 |
| NCPE assessment re-commenced | 14/07/2026 |
| Factual accuracy sent to Applicant | 05/08/2026 |
| NCPE assessment re-commenced | 12/08/2026 |
| NCPE assessment completed | 18/08/2026 |
| NCPE assessment outcome | The NCPE recommends that acalabrutinib in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.